"The major change envisaged is a move away from a trading face centered approach to a therapy area focused approach," the firm said in a statement. "Thus, the three current trading faces of the company - Glaxo Pharmaceuticals, Glaxo Allenburys and Burroughs Wellcome - will devolve into seven business units...," it said. Glaxo India and Burroughs Wellcome (India) are subsidiaries of Britain's Glaxo Wellcome Plc.

Each business unit will have its own distinct team of sales and marketing staff, Glaxo said. It said its portfolio of over 200 products would be rationalised and re-allocated among the business units.